These Biotech Stocks are Just What the Doctor Ordered

The Most Profitable Contrarian Investment Strategies for 2010 and Beyond
The 2010 Investment U Conference is underway! And even if you couldn't make it, now you can "bring home" more than 30 breakthrough presentations from the conference... Order the Deluxe MP3/Video Library for $99 to listen and view on your computer, or the Premier CD plus MP3/Video Library for $149 to listen to and view anywhere.

These Biotech Stocks Are Just What the Doctor Ordered

by Louise Harris, Investment U Research
Thursday, January 28, 2010

They say that one in every nine women will get breast cancer.

It’s a staggering statistic, just like the equally frightening claim that one in four people will end up with some type of cancer in their lifetimes… or that the disease affects 10 million people around the globe every year.

Fortunately, doctors, research teams and entire corporations have set their brilliant minds to finding a viable cure. And they’ve made enormous strides in DNA profiling and the emerging field of pharmacogenomics – which studies how individual genetics affect medication outcomes.

Meanwhile, other companies are developing prophylactic vaccines, which target viruses that lead to cancer. Kalorama Information expects the market to double from the $2 billion recorded in 2008 to just over $4 billion by 2012, creating countless investment opportunities in biotech and healthcare along the way.

The Proof Is In Healthcare’s Past

When looking to invest in healthcare companies which produce therapeutic vaccines that use a patient’s own tissue to develop a therapy or mass-produced immunotherapies, investors need look no further than Gardasil. This cervical cancer vaccine captured the attention of drug companies and the financial world when it first debuted. Other companies in the same league are:

OncoVAX from Vaccinogen: An active-specific immunotherapeutic for the post-surgical treatment of patients with Stage 2 colon cancer
TroVAX from Oxford Bomedica’s: A still developing solution to most solid tumor types.
Lucanix from NovaRX Corp: The drug – now in Phase 3 trials – meant to treat Stage 3 or Stage 4, non-small cell lung cancer.

And the next few years should bring other therapies with them, as clinicians work tirelessly on treating and preventing cancer in all of its forms.

Killing Cancer Has Investment Growth Potential

In 2009, small cap biotech companies Dendreon Corp. (Nasdaq: DNDN), Human Genome Sciences (Nasdaq: HGSI) and ManKind Corp (Nasdaq: MNKD) experienced tremendous growth because of the cancer treatments they had in the works. Share prices gained multi-hundred percentages while leaving investors wanting more.

And there’s more where that came from…

Take Generex Biotechnology Corp. (Nasdaq: GNBT), which produces technology that delivers drugs through the oral cavity without penetrating the lungs. But that’s not all it does. It also has a strong pipeline focused on two different kinds of vaccines:

Those that prevent the immune system from attacking itself while fighting outside threats
And others that stimulate the immune system to attack cancer cells, bacteria and viruses.

These types of treatments could eventually fight seasonal influenza viruses, HIV, melanoma, ovarian cancer, allergies and Type I diabetes mellitus… All huge markets in the drug industry.

If Generex performs the way that it should, the stock could be the next biotech investment success story.

Good investing,

Louise Harris